Page 175 - Remedial Andrology

145. Malkin, C.J., et al. Testosterone therapy in men with moderate severity heart failure: a double-blind
randomized placebo controlled trial. Eur Heart J, 2006. 27: 57.
https://pubmed.ncbi.nlm.nih.gov/16093267
146. Mathur, A., et al. Long-term benefits of testosterone replacement therapy on angina threshold and
atheroma in men. Eur J Endocrinol, 2009. 161: 443.
https://pubmed.ncbi.nlm.nih.gov/19542238
147. EMA. No consistent evidence of an increased risk of heart problems with testosterone medicines.
2014.
https://www.ema.europa.eu/en/news/no-consistent-evidence-increased-risk-heart-problems-
testosterone-medicines
148. FDA. Briefing Information for the September 17, 2014 Joint Meeting of the Bone, Reproductive
and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management
(DSaRM) Advisory Committee Meeting.
https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/
reproductivehealthdrugsadvisorycommittee/ucm530330.pdf
149. Alexander, G.C., et al. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A
Systematic Review and Meta-Analysis. Am J Med, 2017. 130: 293.
https://pubmed.ncbi.nlm.nih.gov/27751897
150. Corona, G., et al. Cardiovascular risk associated with testosterone-boosting medications: a
systematic review and meta-analysis. Expert Opin Drug Saf, 2014. 13: 1327.
https://pubmed.ncbi.nlm.nih.gov/25139126
151. Corona, G., et al. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
J Sex Med, 2018. 15: 820.
https://pubmed.ncbi.nlm.nih.gov/29803351
152. Basaria, S., et al. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis
Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical
Trial. Jama, 2015. 314: 570.
https://pubmed.ncbi.nlm.nih.gov/26262795
153. Budoff, M.J., et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With
Low Testosterone. Jama, 2017. 317: 708.
https://pubmed.ncbi.nlm.nih.gov/28241355
154. Caminiti, G., et al. Effect of long-acting testosterone treatment on functional exercise capacity,
skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with
chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol, 2009.
54: 919.
https://pubmed.ncbi.nlm.nih.gov/19712802
155. Pugh, P.J., et al. Testosterone treatment for men with chronic heart failure. Heart, 2004. 90: 446.
https://pubmed.ncbi.nlm.nih.gov/15020527
156. Sharma, R., et al. Normalization of testosterone level is associated with reduced incidence of
myocardial infarction and mortality in men. Eur Heart J, 2015. 36: 2706.
https://pubmed.ncbi.nlm.nih.gov/26248567
157. Brown, D.W., et al. Hematocrit and the risk of coronary heart disease mortality. Am Heart J, 2001.
142: 657.
https://pubmed.ncbi.nlm.nih.gov/11579356
158. Puddu, P.E., et al. Red blood cell count in short-term prediction of cardiovascular disease incidence
in the Gubbio population study. Acta Cardiol, 2002. 57: 177.
https://pubmed.ncbi.nlm.nih.gov/12088175
159. Boffetta, P., et al. A U-shaped relationship between haematocrit and mortality in a large prospective
cohort study. Int J Epidemiol, 2013. 42: 601.
https://pubmed.ncbi.nlm.nih.gov/23569195
160. Baillargeon, J., et al. Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy.
Mayo Clin Proc, 2015. 90: 1038.
https://pubmed.ncbi.nlm.nih.gov/26205547
161. Sharma, R., et al. Association Between Testosterone Replacement Therapy and the Incidence
of DVT and Pulmonary Embolism: A Retrospective Cohort Study of the Veterans Administration
Database. Chest, 2016. 150: 563.
https://pubmed.ncbi.nlm.nih.gov/27179907
162. Martinez, C., et al. Testosterone treatment and risk of venous thromboembolism: population based
case-control study. BMJ, 2016. 355: i5968.
https://pubmed.ncbi.nlm.nih.gov/27903495

174 SEXUAL AND REPRODUCTIVE HEALTH - MARCH 2021